Benjamin Burnett
Stock Analyst at Wells Fargo
(3.46)
# 934
Out of 5,128 analysts
91
Total ratings
52.24%
Success rate
4.69%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Benjamin Burnett
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AVDL Avadel Pharmaceuticals | Maintains: Equal-Weight | $20 → $23 | $21.50 | +4.65% | 3 | Nov 20, 2025 | |
| CNTA Centessa Pharmaceuticals | Maintains: Overweight | $30 → $35 | $22.69 | +54.25% | 3 | Nov 13, 2025 | |
| ALKS Alkermes | Maintains: Overweight | $42 → $37 | $29.36 | +26.02% | 3 | Nov 13, 2025 | |
| AXSM Axsome Therapeutics | Maintains: Overweight | $163 → $157 | $170.69 | -8.02% | 2 | Nov 4, 2025 | |
| FATE Fate Therapeutics | Maintains: Hold | $5 → $3 | $1.11 | +170.27% | 3 | Mar 6, 2025 | |
| CRSP CRISPR Therapeutics AG | Maintains: Hold | $53 → $49 | $57.99 | -15.50% | 6 | Feb 13, 2025 | |
| ACLX Arcellx | Maintains: Buy | $83 → $122 | $65.01 | +87.66% | 5 | Oct 18, 2024 | |
| BEAM Beam Therapeutics | Maintains: Buy | $66 → $69 | $28.93 | +138.51% | 2 | Sep 11, 2024 | |
| IDYA IDEAYA Biosciences | Maintains: Buy | $63 → $68 | $37.86 | +79.61% | 7 | Sep 10, 2024 | |
| ALLO Allogene Therapeutics | Maintains: Hold | $4.4 → $4.6 | $1.49 | +208.72% | 5 | May 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $120 → $58 | $14.94 | +284.87% | 4 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $690 → $780 | $4.36 | +17,789.91% | 2 | Sep 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $65 → $45 | $24.20 | +85.95% | 1 | Dec 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $7 → $9 | $5.77 | +55.98% | 1 | Dec 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $217 → $234 | $176.00 | +32.95% | 1 | Dec 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $44 → $48 | $42.12 | +13.96% | 3 | Dec 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $16 → $29 | $15.43 | +87.95% | 2 | Dec 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $10 → $8 | $5.85 | +36.75% | 1 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $26 → $23 | $18.56 | +23.92% | 1 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $73 → $93 | $77.24 | +20.40% | 1 | Nov 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $414 → $423 | $503.69 | -16.02% | 1 | Oct 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $78 → $64 | $102.71 | -37.69% | 5 | Apr 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $90 → $94 | $80.94 | +16.14% | 7 | Jan 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 → $4 | $2.56 | +56.25% | 5 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $7 → $10 | $4.85 | +106.19% | 3 | Jun 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $25 | $2.77 | +802.53% | 11 | Sep 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $330 → $360 | $43.51 | +727.40% | 2 | Jun 28, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | $16 | $0.46 | +3,378.26% | 1 | Jan 6, 2021 |
Avadel Pharmaceuticals
Nov 20, 2025
Maintains: Equal-Weight
Price Target: $20 → $23
Current: $21.50
Upside: +4.65%
Centessa Pharmaceuticals
Nov 13, 2025
Maintains: Overweight
Price Target: $30 → $35
Current: $22.69
Upside: +54.25%
Alkermes
Nov 13, 2025
Maintains: Overweight
Price Target: $42 → $37
Current: $29.36
Upside: +26.02%
Axsome Therapeutics
Nov 4, 2025
Maintains: Overweight
Price Target: $163 → $157
Current: $170.69
Upside: -8.02%
Fate Therapeutics
Mar 6, 2025
Maintains: Hold
Price Target: $5 → $3
Current: $1.11
Upside: +170.27%
CRISPR Therapeutics AG
Feb 13, 2025
Maintains: Hold
Price Target: $53 → $49
Current: $57.99
Upside: -15.50%
Arcellx
Oct 18, 2024
Maintains: Buy
Price Target: $83 → $122
Current: $65.01
Upside: +87.66%
Beam Therapeutics
Sep 11, 2024
Maintains: Buy
Price Target: $66 → $69
Current: $28.93
Upside: +138.51%
IDEAYA Biosciences
Sep 10, 2024
Maintains: Buy
Price Target: $63 → $68
Current: $37.86
Upside: +79.61%
Allogene Therapeutics
May 14, 2024
Maintains: Hold
Price Target: $4.4 → $4.6
Current: $1.49
Upside: +208.72%
Apr 1, 2024
Maintains: Hold
Price Target: $120 → $58
Current: $14.94
Upside: +284.87%
Sep 10, 2021
Maintains: Buy
Price Target: $690 → $780
Current: $4.36
Upside: +17,789.91%
Dec 30, 2025
Maintains: Overweight
Price Target: $65 → $45
Current: $24.20
Upside: +85.95%
Dec 18, 2025
Maintains: Overweight
Price Target: $7 → $9
Current: $5.77
Upside: +55.98%
Dec 16, 2025
Maintains: Overweight
Price Target: $217 → $234
Current: $176.00
Upside: +32.95%
Dec 11, 2025
Maintains: Overweight
Price Target: $44 → $48
Current: $42.12
Upside: +13.96%
Dec 9, 2025
Maintains: Overweight
Price Target: $16 → $29
Current: $15.43
Upside: +87.95%
Nov 11, 2025
Maintains: Overweight
Price Target: $10 → $8
Current: $5.85
Upside: +36.75%
Nov 11, 2025
Maintains: Overweight
Price Target: $26 → $23
Current: $18.56
Upside: +23.92%
Nov 5, 2025
Maintains: Overweight
Price Target: $73 → $93
Current: $77.24
Upside: +20.40%
Oct 30, 2025
Maintains: Equal-Weight
Price Target: $414 → $423
Current: $503.69
Upside: -16.02%
Apr 1, 2025
Maintains: Buy
Price Target: $78 → $64
Current: $102.71
Upside: -37.69%
Jan 24, 2025
Maintains: Buy
Price Target: $90 → $94
Current: $80.94
Upside: +16.14%
Dec 13, 2024
Maintains: Buy
Price Target: $9 → $4
Current: $2.56
Upside: +56.25%
Jun 3, 2024
Maintains: Buy
Price Target: $7 → $10
Current: $4.85
Upside: +106.19%
Sep 15, 2023
Reiterates: Buy
Price Target: $25
Current: $2.77
Upside: +802.53%
Jun 28, 2021
Upgrades: Buy
Price Target: $330 → $360
Current: $43.51
Upside: +727.40%
Jan 6, 2021
Initiates: Hold
Price Target: $16
Current: $0.46
Upside: +3,378.26%